Broadcast Date: October 7th, 2014

Traumatic Brain Injury (TBI) has garnered significant media attention recently as evidence has mounted that concussions due to sports injuries, in the battlefield, and even in everyday accidents can have long term effects on brain health.  Currently, no simple blood test exists to diagnose TBI, greatly limiting the ability to properly identify and care for patients who have suffered a head injury.  Quanterix’ Simoa digital immunoassay technology has achieved a level of sensitivity sufficient to measure brain biomarkers in blood for the first time, opening new avenues for brain injury research and the potential for an easy blood-based diagnostic test.

Quanterix is a developer of ground-breaking tools in high-definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit:www.quanterix.com or email sales@quanterix.com.

Produced with support from:

Sponsor Logo

Panelists

Julien N. Bradley,
Senior Director,
Quanterix

Jeffrey Randall, Ph.D.
Principal Scientist,
Quanterix